Glutamine
Undifferentiated High Grade Pleomorphic Sarcoma Of Bone
Explore 5 assets in Undifferentiated High Grade Pleomorphic Sarcoma Of Bone →Floatz Rating
D30/100
Confidence
Indicative
Sponsor
Children's Oncology Group
Modality
Small molecule
Development Phase
N/A
Status
Dormant
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
15Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT00334984CT.gov Glutamine in Preventing Oral Mucositis in Patients Receiving Chemotherapy for Sarcoma | — | Withdrawn | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Undifferentiated High Grade Pleomorphic Sarcoma Of Bone
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Glutamine (this asset) | Children's Oncology Group | N/A | D · 30 |
| Fludarabine | M.D. Anderson Cancer Center | P2 | CCC |
| Ipilimumab | M.D. Anderson Cancer Center | P2 | CCC |
| Nivolumab | M.D. Anderson Cancer Center | P2 | CCC |
| Cyclophosphamide | M.D. Anderson Cancer Center | P2 | CCC |
| Lifileucel | M.D. Anderson Cancer Center | P2 | CCC |
| Vismodegib | National Cancer Institute (NCI) | P1/2 | CCC |
| RG 4733 | National Cancer Institute (NCI) | P1/2 | CC |
Other indications for Glutamine
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Sickle Cell Disease | — | P4 | BBB · 72 |
| Duchenne Muscular Dystrophy | — | P3 | BB · 68 |
| Peripheral Neuropathy | — | P3 | B · 62 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Glutamine in Undifferentiated High Grade Pleomorphic Sarcoma Of Bone. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/glutamine-undifferentiated-high-grade-pleomorphic-sarcoma-of-bone
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →